{
    "info": {
        "nct_id": "NCT05660395",
        "official_title": "A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)",
        "inclusion_criteria": "* Male or female participants aged 18 years or older\n* Pathologic diagnosis of relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) DLBCL not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma (2016 World Health Organization classification) who have received at least one systemic treatment regimen\n* Measurable disease as defined by the 2014 Lugano Classification\n* Normal hepatic function or hepatic impairment as defined by the National Cancer Institute Organ Dysfunction Working Group hepatic impairment classification:\n\n  * Arm A Normal hepatic function: bilirubin and aspartate aminotransferase (AST) ≤ upper limit of normal (ULN)\n  * Arm B Moderate hepatic impairment: bilirubin > 1.5 × to 3 × ULN (any AST)\n  * Arm C Severe hepatic impairment: bilirubin > 3 × ULN (any AST)\n* ECOG performance status 0 to 2 for participants with normal hepatic function. ECOG 0 to 3 for participants with moderate or severe hepatic impairment\n* Adequate organ function\n* Women of childbearing potential (WOCBP)* must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of the first dose until at least 7 months after the last dose of study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Previous therapy with loncastuximab tesirine\n* Allogenic or autologous stem cell transplant within 60 days prior to start of study drug (C1D1)\n* Human immunodeficiency virus (HIV) seropositive\n* Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load\n* Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load\n* History of Stevens-Johnson syndrome or toxic epidermal necrolysis\n* Lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease\n* Breastfeeding or pregnant\n* Significant medical comorbidities\n* Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy, within 14 days prior to start of study drug (C1D1), except shorter if approved by the Sponsor",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Measurable disease as defined by the 2014 Lugano Classification",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined by the 2014 Lugano Classification",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "2014 Lugano Classification"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm A Normal hepatic function: bilirubin and aspartate aminotransferase (AST) ≤ upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "bilirubin ... ≤ upper limit of normal (ULN)",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ≤ upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP)* must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of the first dose until at least 7 months after the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) ... must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug.",
                    "criterion": "contraception use (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "contraception use period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from informed consent to 10 months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of the first dose until at least 7 months after the last dose of study drug.",
                    "criterion": "contraception/abstinence (men with female partners of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use condom or abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception/abstinence period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from first dose to 7 months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm C Severe hepatic impairment: bilirubin > 3 × ULN (any AST)",
            "criterions": [
                {
                    "exact_snippets": "bilirubin > 3 × ULN",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(any AST)",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "any"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arm B Moderate hepatic impairment: bilirubin > 1.5 × to 3 × ULN (any AST)",
            "criterions": [
                {
                    "exact_snippets": "Arm B Moderate hepatic impairment: bilirubin > 1.5 × to 3 × ULN",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Arm B Moderate hepatic impairment: ... (any AST)",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "any"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status 0 to 2 for participants with normal hepatic function. ECOG 0 to 3 for participants with moderate or severe hepatic impairment",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0 to 2 for participants with normal hepatic function",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "normal hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                },
                {
                    "exact_snippets": "ECOG 0 to 3 for participants with moderate or severe hepatic impairment",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "moderate or severe hepatic impairment",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Normal hepatic function or hepatic impairment as defined by the National Cancer Institute Organ Dysfunction Working Group hepatic impairment classification:",
            "criterions": [
                {
                    "exact_snippets": "Normal hepatic function or hepatic impairment as defined by the National Cancer Institute Organ Dysfunction Working Group hepatic impairment classification",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "normal",
                                "impaired (per NCI Organ Dysfunction Working Group classification)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female participants aged 18 years or older",
            "criterions": [
                {
                    "exact_snippets": "Male or female participants",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "aged 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologic diagnosis of relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) DLBCL not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma (2016 World Health Organization classification) who have received at least one systemic treatment regimen",
            "criterions": [
                {
                    "exact_snippets": "Pathologic diagnosis of relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) DLBCL not otherwise specified",
                    "criterion": "DLBCL not otherwise specified",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "DLBCL arising from low grade lymphoma",
                    "criterion": "DLBCL arising from low grade lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "high-grade B-cell lymphoma (2016 World Health Organization classification)",
                    "criterion": "high-grade B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "classification",
                            "expected_value": "2016 World Health Organization"
                        }
                    ]
                },
                {
                    "exact_snippets": "who have received at least one systemic treatment regimen",
                    "criterion": "systemic treatment regimen",
                    "requirements": [
                        {
                            "requirement_type": "number received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "Lymphoma with active central nervous system involvement at the time of screening",
                    "criterion": "central nervous system involvement by lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "including leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load",
            "criterions": [
                {
                    "exact_snippets": "Serologic evidence of hepatitis C virus (HCV) infection",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "serologic evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without completion of curative treatment",
                    "criterion": "curative treatment for HCV infection",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "with detectable HCV viral load",
                    "criterion": "HCV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectable",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of Stevens-Johnson syndrome or toxic epidermal necrolysis",
            "criterions": [
                {
                    "exact_snippets": "History of Stevens-Johnson syndrome",
                    "criterion": "Stevens-Johnson syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... toxic epidermal necrolysis",
                    "criterion": "toxic epidermal necrolysis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allogenic or autologous stem cell transplant within 60 days prior to start of study drug (C1D1)",
            "criterions": [
                {
                    "exact_snippets": "Allogenic or autologous stem cell transplant within 60 days prior to start of study drug (C1D1)",
                    "criterion": "stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "allogenic",
                                "autologous"
                            ]
                        },
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days prior to start of study drug (C1D1)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant medical comorbidities",
            "criterions": [
                {
                    "exact_snippets": "Significant medical comorbidities",
                    "criterion": "medical comorbidities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Human immunodeficiency virus (HIV) seropositive",
            "criterions": [
                {
                    "exact_snippets": "Human immunodeficiency virus (HIV) seropositive",
                    "criterion": "HIV serostatus",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy, within 14 days prior to start of study drug (C1D1), except shorter if approved by the Sponsor",
            "criterions": [
                {
                    "exact_snippets": "Major surgery ... within 14 days prior to start of study drug (C1D1)",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy ... within 14 days prior to start of study drug (C1D1)",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy ... within 14 days prior to start of study drug (C1D1)",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other anti-neoplastic therapy, within 14 days prior to start of study drug (C1D1)",
                    "criterion": "other anti-neoplastic therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load",
            "criterions": [
                {
                    "exact_snippets": "Serologic evidence of chronic hepatitis B virus (HBV) infection",
                    "criterion": "chronic hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "serologic evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable or unwilling to receive standard prophylactic antiviral therapy",
                    "criterion": "standard prophylactic antiviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "ability or willingness to receive",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "detectable HBV viral load",
                    "criterion": "HBV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectable",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Breastfeeding or pregnant",
            "criterions": [
                {
                    "exact_snippets": "Breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous therapy with loncastuximab tesirine",
            "criterions": [
                {
                    "exact_snippets": "Previous therapy with loncastuximab tesirine",
                    "criterion": "previous therapy with loncastuximab tesirine",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}